ReviewNature reviews. Cardiology2024
Atherosclerotic plaque stabilization and regression: a review of clinical evidence.
Review in Nature reviews. Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Pooled it
- Association between serum bilirubin levels and carotid atherosclerosis: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Epitranscriptomic profiling of VSMC phenotypes reveals uridine modifications linked to post-transcriptional regulation.Biochemistry and biophysics reports · 2026Article
- Review
- Serial Molecular-Microstructural Multimodal Intravascular Imaging of Atherosclerotic Plaques in Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- A foam cell-targeted lipophagy restoration strategy stabilizes vulnerable atherosclerotic plaques.Bioactive materials · 2026Article
- Review
- Atherosclerotic Plaque Characterization Magnetic Resonance Imaging In Vitro at 1.5 Tesla for the Assessment of Coronary Artery Disease.Journal of clinical medicine · 2026Article
- Dysregulated Sheddase Signalling as a Molecular Driver of Plaque Instability Revealed by Integrative Transcriptomics.Journal of cellular and molecular medicine · 2026Article
- Hemodynamic Study of Plaque Progression and Regression Based on Coronary CTA Imaging using Computational Fluid Dynamics Method: Preliminary Results.Journal of cardiovascular translational research · 2026Article
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- The neuroimmune axis in cardiovascular disease: from immune activation to inflammatory resolution.Frontiers in immunology · 2026Review
- Efficacy and safety of Shenqi Yangxin formula in patients with stable coronary artery disease based on CCTA: rationale, design, and study protocol for a randomized, double-blind, placebo-controlled study.Frontiers in cardiovascular medicine · 2026Article
- PI3K/AKT signaling pathway: new strategies for treating atherosclerosis with plant-derived compounds.Frontiers in pharmacology · 2026Review
- Remnant cholesterol: a risk stratification aid for coronary artery stenosis severity in patients with type 2 diabetes.Frontiers in medicine · 2026Article
- Reappraising heme oxygenase-1 as a ferroptosis modulator in atherosclerosis: a mechanism-focused review.Frontiers in immunology · 2026Review
- Caspase Recruitment Domain Family Member 8: A Favorable Target in the Pathogenesis of Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- Decoding the crosstalk: interplay between macrophage programmed cell death networks and cholesterol efflux.Frontiers in cardiovascular medicine · 2026Review
- Aqueous Extract ofNutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic plaque results from a complex interplay between lipid deposition, inflammatory changes, cell migration and arterial wall injury. Over the past two decades, clinical trials utilizing invasive arterial imaging modalities, such as intravascular ultrasonography, have shown that reducing levels of atherogenic lipoproteins, mainly serum LDL-cholesterol (LDL-C), to very low levels can safely reduce overall atherosclerotic plaque burden and favourably modify plaque composition. Classically, this outcome has been achieved with intensive statin therapy. Since 2016, newer and potent lipid-lowering strategies, such as proprotein convertase subtilisin-kexin type 9 inhibition, have shown incremental effects on plaque regression and risk of clinical events. Despite maximal reduction in plasma LDL-C levels, considerable residual cardiovascular risk remains in some patients. Therefore, there is a need to study therapeutic approaches that address residual risk beyond LDL-C reduction to promote plaque stabilization or regression. Contemporary imaging modalities, such as coronary computed tomography angiography, enable non-invasive assessment of the overall atherosclerotic plaque burden as well as of certain local plaque characteristics. This technology could allow further study of plaque stabilization and regression using novel therapeutic approaches. Non-invasive plaque assessment might also offer the potential to guide personalized management strategies if validated for this purpose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.